Marfan syndrome: a therapeutic challenge for long-term care
Marfan syndrome (MFS) is an autosomal dominant genetic disorder caused by mutations in the fibrillin-1 gene. Acute aortic dissection is the leading cause of death in patients suffering from MFS and consequence of medial degeneration and aneurysm formation. In addition to its structural function in t...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
June 2019
|
| In: |
Biochemical pharmacology
Year: 2019, Volume: 164, Pages: 53-63 |
| ISSN: | 1873-2968 |
| DOI: | 10.1016/j.bcp.2019.03.034 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1016/j.bcp.2019.03.034 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0006295219301200 
|
| Author Notes: | A.H. Wagner, M. Zaradzki, R. Arif, A. Remes, O.J. Müller, K. Kallenbach |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1668132249 | ||
| 003 | DE-627 | ||
| 005 | 20230426163612.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190701s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bcp.2019.03.034 |2 doi | |
| 035 | |a (DE-627)1668132249 | ||
| 035 | |a (DE-599)KXP1668132249 | ||
| 035 | |a (OCoLC)1341231588 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Wagner, Andreas H. |d 1963- |e VerfasserIn |0 (DE-588)1047559080 |0 (DE-627)778552381 |0 (DE-576)401158144 |4 aut | |
| 245 | 1 | 0 | |a Marfan syndrome |b a therapeutic challenge for long-term care |c A.H. Wagner, M. Zaradzki, R. Arif, A. Remes, O.J. Müller, K. Kallenbach |
| 264 | 1 | |c June 2019 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 01.07.2019 | ||
| 520 | |a Marfan syndrome (MFS) is an autosomal dominant genetic disorder caused by mutations in the fibrillin-1 gene. Acute aortic dissection is the leading cause of death in patients suffering from MFS and consequence of medial degeneration and aneurysm formation. In addition to its structural function in the formation of elastic fibers, fibrillin has a major role in keeping maintaining transforming growth factor β (TGF-β) in an inactive form. Dysfunctional fibrillin increases TGF-β bioavailability and concentration in the extracellular matrix, leading to activation of proinflammatory transcription factors. In turn, these events cause increased expression of matrix metalloproteinases and cytokines that control the migration and infiltration of inflammatory cells into the aorta. Moreover, TGF-β causes accumulation of reactive oxygen species leading to further degradation of elastin fibers. All these processes result in medial elastolysis, which increases the risk of vascular complications. Although MFS is a hereditary disease, symptoms and traits are usually not noticeable at birth. During childhood or adolescence affected individuals present with severe tissue weaknesses, especially in the aorta, heart, eyes, and skeleton. Considering this, even young patients should avoid activities that exert additional stress and pressure on the aorta and the cardiovascular system. Thus, if the diagnosis is made and prophylactic treatment is initiated in a timely fashion, MFS and its preliminary pathophysiologic vascular remodeling can be successfully ameliorated reducing the risk of life-threatening complications. This commentary focuses on new research opportunities and molecular findings on MFS, discusses future challenges and possible long-term therapies. | ||
| 650 | 4 | |a Fibrillin | |
| 650 | 4 | |a Gender | |
| 650 | 4 | |a Marfan syndrome | |
| 650 | 4 | |a Therapy | |
| 650 | 4 | |a Transforming growth factor β | |
| 700 | 1 | |a Zaradzki, Marcin |e VerfasserIn |0 (DE-588)1139366491 |0 (DE-627)897129539 |0 (DE-576)493241914 |4 aut | |
| 700 | 1 | |a Arif, Rawa |d 1984- |e VerfasserIn |0 (DE-588)1023582775 |0 (DE-627)718414071 |0 (DE-576)367034530 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biochemical pharmacology |d Amsterdam [u.a.] : Elsevier Science, 1958 |g 164(2019), Seite 53-63 |h Online-Ressource |w (DE-627)30631777X |w (DE-600)1496199-4 |w (DE-576)081952929 |x 1873-2968 |7 nnas |a Marfan syndrome a therapeutic challenge for long-term care |
| 773 | 1 | 8 | |g volume:164 |g year:2019 |g pages:53-63 |g extent:11 |a Marfan syndrome a therapeutic challenge for long-term care |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.bcp.2019.03.034 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0006295219301200 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190701 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1023582775 |a Arif, Rawa |m 1023582775:Arif, Rawa |d 910000 |d 910200 |e 910000PA1023582775 |e 910200PA1023582775 |k 0/910000/ |k 1/910000/910200/ |p 3 | ||
| 998 | |g 1139366491 |a Zaradzki, Marcin |m 1139366491:Zaradzki, Marcin |d 910000 |d 910200 |e 910000PZ1139366491 |e 910200PZ1139366491 |k 0/910000/ |k 1/910000/910200/ |p 2 | ||
| 998 | |g 1047559080 |a Wagner, Andreas H. |m 1047559080:Wagner, Andreas H. |d 50000 |d 53200 |e 50000PW1047559080 |e 53200PW1047559080 |k 0/50000/ |k 1/50000/53200/ |p 1 |x j | ||
| 999 | |a KXP-PPN1668132249 |e 3490293592 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"title":[{"subtitle":"a therapeutic challenge for long-term care","title_sort":"Marfan syndrome","title":"Marfan syndrome"}],"note":["Gesehen am 01.07.2019"],"origin":[{"dateIssuedDisp":"June 2019","dateIssuedKey":"2019"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"given":"Andreas H.","role":"aut","display":"Wagner, Andreas H.","family":"Wagner"},{"role":"aut","given":"Marcin","family":"Zaradzki","display":"Zaradzki, Marcin"},{"role":"aut","given":"Rawa","display":"Arif, Rawa","family":"Arif"}],"id":{"eki":["1668132249"],"doi":["10.1016/j.bcp.2019.03.034"]},"relHost":[{"disp":"Marfan syndrome a therapeutic challenge for long-term careBiochemical pharmacology","part":{"extent":"11","volume":"164","year":"2019","pages":"53-63","text":"164(2019), Seite 53-63"},"note":["Gesehen am 21.02.20"],"origin":[{"publisher":"Elsevier Science","dateIssuedKey":"1958","publisherPlace":"Amsterdam [u.a.]","dateIssuedDisp":"1958-"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title":"Biochemical pharmacology","title_sort":"Biochemical pharmacology"}],"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"recId":"30631777X","pubHistory":["1.1958 -"],"id":{"issn":["1873-2968"],"eki":["30631777X"],"zdb":["1496199-4"]}}],"recId":"1668132249","physDesc":[{"extent":"11 S."}],"name":{"displayForm":["A.H. Wagner, M. Zaradzki, R. Arif, A. Remes, O.J. Müller, K. Kallenbach"]}} | ||
| SRT | |a WAGNERANDRMARFANSYND2019 | ||